# US 5,858,996 A · Compositions and methods for stabilizing polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,996 A
- Document ID: US5858996A
- Status: Granted
- Kind: A
- Application number: 08/863,855
- Filed: 1997-05-27
- Granted: 1999-01-12
- Earliest claimed: 1995-06-22
- Assignees: CIBA Vision Corporation
- Inventors: Fu-Pao Tsao
- Web page: https://patentgrep.com/patent/US5858996A

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/02: Ophthalmic agents
- C08K 5/5317: Phosphonic compounds, e.g. R—P(:O)(OR')2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08K: Use of inorganic or non-macromolecular organic substances as compounding ingredients (paints, inks, varnishes, dyes, polishes, adhesives C09)

## Abstract

Compositions and methods for reducing the decomposition rate of polymeric bioadhesives and viscosity enhancers, such as poly(acrylic acids). The compositions include at least one strong, stable chelating agent, preferably an organophosphorous compound such as diethylene triamine penta(methylene phosphonic acid). These biocompatible compositions are especially useful in the ophthalmic field.

## Claims

### Claim 1

A stabilized composition, comprising:
(a) about 0.1 to 2.0 weight percent of at least one polymer selected from the group consisting of poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids and mixtures thereof; and
(b) at least one strong and stable amino tri(lower alkylene phosphonic acid) chelating agent in an amount of about 0.0001 to 0.1 weight percent; and
(c) water.

### Claim 2 (depends on 1)

A composition of claim 1, wherein said composition is ophthalmically compatible.

### Claim 3 (depends on 2)

A composition of claim 2, further including an ophthalmic delivery agent.

### Claim 4 (depends on 3)

A composition of claim 3, wherein said ophthalmic delivery agent is selected from the group consisting of ophthalmically beneficial pharmaceutical agents, diagnostic agents, vitamins, nutrients, lubricants, and mixtures thereof.

### Claim 5 (depends on 4)

A composition of claim 4, wherein said ophthalmic delivery agent is selected from the group consisting of 3H-thymidine, acetylcholine chloride, acyclovir, adrenaline, amethocaine, aminocaproic acid, antazoline phosphate, arachidonic acid, atropine, benoxinate hydrochloride, betaxolol hydrochloride, bupivacaine, carbachol, carteolol, chloramphenicol, chlortetracycline hydrochloride, chymatrypsin, clonidine, cocaine, corynanthine, cromolyn sodium, cyclopentolate, demecarium bromide, dexamethasone, dibutoline, dichlorphenamide, diclofenac, dipivefrin hydrochloride, echodtiophate iodide, ephedrine, epinephrine bitartrate, erythromycin, ethambutol, etidocaine, eucatropine, fluoromethalone, fluorometholone, gentamicin sulfate, gramicidine, H-thymidine, homatropine hydrobromide, hyaluronic acid, hydrocortisone, idoxuridine, indomethacin, inositol triphosphate, inositol phosphates, isoflurophate, isosorbide, lachesine, levobunolol, levocabastine, lidocaine, lignocaine, medrysone, mepivacaine, methacholine, methazolamide, naphazoline hydrochloride, natamycin, neomycin sulfate, neostigmine, noradrenaline, ofloxacin, oxybuprocaine, oxymetazolin, oxyphenonium, pheniramine maleate, phenylephrine hydrochloride, phosphatidylinositol phosphates, physostigmine, pilocarpine hydrochloride, polyhexamethylene biguanides, polymyxin B sulfates, prednisolone sodium phosphate, proparacaine hydrochloride, proxymethacaine, pyrilamine maleate, scopolamine hydrobromide, sorbinil, sulfacetamide, sulfisoxazole disolamine, tamoxifen, tetracaine hydrochloride, tetracycline, tetrahydrozoline hydrochloride, timolol maleate and hemihydrate, trifluridine, tropicamide, vidarabine, other ophthalmically acceptable salts thereof and mixtures thereof.

### Claim 6 (depends on 1)

A composition of claim 1, wherein said polymer is a poly(acrylic acid). phosphonic acid).

### Claim 7 (depends on 1)

A composition of claim 1, wherein said chelating agent is selected from the group consisting of diethylene triamine penta(methylene phosphonic acid); hexamethylene-diaminetetra (methylenephosphonic acid); ethylenediaminetetra (methylenephosphonic acid); aminotrimethylene phosphonates; and mixtures thereof.

### Claim 8 (depends on 7)

A composition of claim 7, wherein said chelating agent is diethylene triamine penta(methylene phosphonic acid).

### Claim 9 (depends on 1)

A composition of claim 1, further comprising about 0.1 to 2.0 weight percent poly(alkylene glycol).

### Claim 10 (depends on 1)

A composition of claim 1, further comprising about 0.6 to 1.2 weight percent of a tonicity enhancer.

### Claim 11 (depends on 10)

A composition of claim 10, wherein said tonicity enhancer is sodium chloride.

### Claim 12 (depends on 1)

A composition of claim 1, further comprising about 0.05 to 5.0 weight percent of a glucose biopolymer.

### Claim 13 (depends on 12)

A composition of claim 12, wherein said glucose biopolymer is dextran.

### Claim 14 (depends on 1)

A composition of claim 1, comprising:
(a) about 0.01 to 2.0 weight percent of said polymer;
(b) about 0.0001 to 0.1 weight percent of said chelating agent;
(c) about 0.1 to 2.0 weight percent poly(alkylene glycol);
(d) about 0 to 1.2 weight percent of a tonicity enhancer;
(e) about 0.05 to 5.0 weight percent of a glucose biopolymer;
(f) about 0.001 to 10 weight percent of a delivery agent; and
(g) water.

### Claim 15 (depends on 14)

A composition of claim 14, comprising:
(a) about 0.01 to 2.0 weight percent of a polymer selected from the group consisting of poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids, and mixtures thereof,
(b) about 0.0001 to 0.1 weight percent of an organophosphorus chelating agent;
(c) about 0.1 to 2.0 weight percent poly(alkylene glycol) selected from the group consisting of polyethylene glycol, polypropylene glycol, and mixtures thereof;
(d) about 0 to 1.2 weight percent of an ophthalmically compatible alkali halide tonicity enhancer;
(e) about 0.05 to 5.0 weight percent of a glucose biopolymer;
(f) about 0.001 to 10.0 weight percent of a delivery agent; and
(g) water.

### Claim 16

A method of stabilizing a polymer composition, comprising the steps of:
(a) providing an ophthalmically compatible composition including about 0.1 to 2.0 weight percent of a polymer selected from the group consisting of poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids and mixtures thereof;
(b) adding at least one strong and stable amino tri(lower alkylene phosphonic acid) chelating agent in an amount of about 0.0001 to 0.1 weight percent and water; and
(c) allowing said chelating agent to complex with free catalytic metal ions, thereby producing a composition with metal ion complexes, whereby the polymer in said composition has a decomposition rate which is less than the decomposition rate of the uncomplexed composition.

### Claim 17 (depends on 16)

A method of claim 16, further including an ophthalmic delivery agent selected from the group consisting of ophthalmic beneficial pharmaceutical agents, diagnostic agents, vitamins, nutrients, lubricants, and mixtures thereof.

### Claim 18 (depends on 16)

A method of claim 16, wherein said chelating agent is selected from the group consisting of diethylene triamine penta(methylene phosphonic acid); hexamethylene-diaminetetra (methylenephosphonic acid); ethylenediaminetetra (methylenephosphonic acid); aminotrimethylene phosphonates; and mixtures thereof.

### Claim 19 (depends on 18)

A method of claim 18, wherein said chelating agent is diethylene triamine penta(methylene phosphonic acid).

### Claim 20 (depends on 16)

A method of claim 16, wherein said polymer composition comprises:
(a) about 0.01 to 2.0 weight percent of said polymer;
(b) about 0.0001 to 0.1 weight percent of said chelating agent;
(c) about 0.1 to 2.0 weight percent poly(alkylene glycol);
(d) about 0 to 1.2 weight percent of a tonicity enhancer;
(e) about 0.05 to 5.0 weight percent of a glucose biopolymer;
(f) about 0.001 to 10 weight percent of a delivery agent; and
(g) water.

### Claim 21 (depends on 20)

A method of claim 20, wherein said polymer composition comprises:
(a) about 0.01 to 2.0 weight percent of a polymer selected from the group consisting of poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids, and mixtures thereof;
(b) about 0.0001 to 0.1 weight percent of an organophosphorus chelating agent;
(c) about 0.1 to 2.0 weight percent poly(alkylene glycol) selected from the group consisting of polyethylene glycol, polypropylene glycol, and mixtures thereof;
(d) about 0 to 1.2 weight percent of an ophthalmically compatible alkali halide tonicity enhancer;
(e) about 0.05 to 5.0 weight percent of a glucose biopolymer;
(f) about 0.001 to 10 weight percent of a delivery agent; and
(g) water.
